Effect of fluvoxamine on cytokine in COVID-19 patients

Phase 2

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20131115015405N4
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Informed consent
Being conscious
Definite diagnosis of COVID-19 in medical records of the patient
Age over 18 years old
Normal serum level of Creatinine, Blood Ureh Nitrogen, White Blood Cell, Potassium, Sodium and Fasting Blood Sugar

Exclusion Criteria

Being pregnant.
Existence of ASA, Warfarin, MAOI, Lithium, Clomipramine, NSAIDs, Methadone, Capropril, Diltiazem and Zolpidem drugs in medical files of the patient.
Simultaneous consumption of any kind of alcohol or substance.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Interlukine - 6 (IL-6) level will be measured in COVID-19 patients. Timepoint: The Interlukine - 6 level will be measured both before the consumption of Fluvoxamine drug and when discharging from the ICU ward. Method of measurement: Measuring kit of Interlukine - 6 by blood test.;Erythrocyte Sedimentation Rate (ESR) level will be measured in COVID-19 patients. Timepoint: The Erythrocyte Sedimentation Rate (ESR) level will be measured both before the consumption of Fluvoxamine drug and when discharging from the ICU ward. Method of measurement: Measuring kit of Erythrocyte Sedimentation Rate (ESR) by blood test.;C-Reactive Protein (CRP) level will be measured in COVID-19 patients. Timepoint: The C-Reactive Protein (CRP) level will be measured both before the consumption of Fluvoxamine drug and when discharging from the ICU ward. Method of measurement: Measuring kit of C-Reactive Protein (CRP) by blood test.